List view / Grid view




TxCell reports revenues for the third quarter of 2014

5 November 2014 | By TxCell

TxCell (FR0010127662 - TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today reports its revenues(1) as of September 30, 2014...